Gwaltney J M, Adams K F, Hendley J O
J Infect Dis. 1977 Dec;136 Suppl:S491-5. doi: 10.1093/infdis/136.supplement_3.s491.
Influenza A/Victoria/75 virus vaccines were tested for acceptability and antigenicity in adults of different ages. Whole-virus vaccines prepared by Merck Sharp and Dohme (West Point, Pa.) and Merrell-National Laboratories (Cincinnati, Ohio) and subunit vaccines prepared by Parke, Davis and Company (Detroit, Mich.) and Wyeth Laboratories (Philadelphia, Pa.) were given intramuscularly in concentrations of 800, 400, or 200 chick cell-agglutinating units per dose. Systemic and local side effects of all vaccine preparations were negligible. In volunteers with low or absent (less than or equal to 10) titers of hemagglutination-inhibiting antibody before vaccination, titers of greater than or equal to 40 were attained after vaccination in 43%-67%, 40%-58%, and 20%-38% of volunteers receiving the 800, 400, and 200 chick cell-agglutinating unit preparations, respectively.
对甲型/维多利亚/75 病毒疫苗在不同年龄段的成年人中进行了可接受性和抗原性测试。由默克夏普&多贺美公司（宾夕法尼亚州西点）、梅里尔-国家实验室（俄亥俄州辛辛那提）制备的全病毒疫苗，以及由帕克-戴维斯公司（密歇根州底特律）、惠氏实验室（宾夕法尼亚州费城）制备的亚单位疫苗，均以每剂 800、400 或 200 鸡胚细胞凝集单位的浓度进行肌肉注射。所有疫苗制剂的全身和局部副作用均可忽略不计。在接种疫苗前血凝抑制抗体滴度较低或无（小于或等于 10）的志愿者中，分别有 43%-67%、40%-58%和 20%-38%接受 800、400 和 200 鸡胚细胞凝集单位制剂的志愿者在接种后滴度达到大于或等于 40。
